Investor FAQs
|
|
- Corporate information |
|
- Equity shares information |
|
- Investor calendar |
- Investor contact information
|
Corporate Information
|
| 1. What is Biocon’s area of operations? |
Biocon is an integrated biotechnology enterprise focused on the development of biopharmaceuticals. The Biocon group of companies consists of Biocon - the flagship, holding company and its subsidiaries, Syngene, Clinigene and a joint venture company, Biocon Biopharmaceuticals. Principal areas of operations include:
|
|
Biopharmaceuticals
|
Biocon’s pharmaceuticals business comprises the manufacture and development of active pharmaceuticals ingredients (APIs) and bulk drugs, with a focus on products involving fermentation and/or synthetic conversion. Our biopharmaceuticals business, however, primarily seeks to leverage the expiry of product patents for key Statins - Simvastatin, Lovastatin, Atorvastatin and Pravastatin through research capabilities and fermentation and synthetic chemistry skills that have been developed over the years at Biocon.
|
| Custom & Clinical Research Services |
Biocon provides contract research services to overseas and domestic customers in the following areas:
|
|
- Molecular Biology |
|
- Synthetic Chemistry |
|
- Bioinformatics |
- Clinical research on well-defined and
characterised patients suffering from chronic diseases such as diabetes,
osteoporosis, asthma, etc.
|
| 2. What is the address of Biocon’s registered office? |
|
Biocon has its corporate and registered office at Bangalore.
|
BIOCON LIMITED
20th KM, Hosur Road
Electronic City PO
Bangalore - 560 100
Ph +91 80 2808 2808
Fax +91 80 2852 3423
|
|
3. Where and in which year was Biocon incorporated?
|
Biocon was incorporated on November 11, 1978 in Bangalore, India.
|
|
4. What is the total employee strength at Biocon Group?
|
Team Biocon comprises of a total employee strength in excess of 2800 employees in various field, with a strong scientist portfolio.
|
| 5. What is Biocon’s revenue and profits for the recently concluded quarter and for the last 12 months? |
|
Q4 FY07 |
FY 07 |
| Revenues |
280 |
990 |
| Profit After Tax |
60 |
200 |
|
6. Where can I obtain information on Biocon’s financial results? |
To obtain the financial results of the company, please refer to our website under the Investor Relations. Alternatively, the same is also available at the website of National Stock Exchange (NSE) and Mumbai Stock Exchange (BSE).
|
The results of the company are also published in Business Daily, Business Standard.
|
| 7. Who are the members on Biocon’s Board of Directors? |
|
Biocons' Board consists of:
|
|
Dr. Kiran Mazumdar-Shaw, Chairman and Managing Director
|
|
Mr. John Shaw
|
|
Dr. Neville Bain
|
|
Prof Charles L Cooney
|
|
Mr. Suresh Talwar
|
|
Prof Ravi Mazumdar
|
|
Dr. Bala Manian
|
Prof Catherine Rosenberg, Alternate Director
|
Equity Shares Information
|
|
1. When did Biocon have its Initial Public Offer (IPO) ?
|
In March 2004, Biocon went public with an IPO of 10,000,000 fresh equity shares of Rs. 5 each at a price of Rs. 315 per share.
|
|
2. On which stock exchanges are Biocon shares listed and what are the codes?
|
| Name of Exchange |
Code |
| National Stock Exchange, Mumbai (NSE) |
BIOCON |
| Mumbai Stock Exchange, (BSE) |
532523 |
|
3. Where can I obtain details on Biocon’s stockholders? |
Details of shareholding pattern of the company as at March 31, 2007 is available in the Annual Report, downloadable from our website. The same is also available on the NSE and BSE websites.
|
|
4. Does Biocon pay dividends?
|
The Company declared a final dividend of 60% for the fiscal year 2007.
|
|
5. What is the percentage breakdown of shareholders?
|
|
The shareholding pattern of Biocon shares as at March 31, 2007
|
| Employees and ESOP Trust |
12% |
| Promoters |
60% |
| Public and Institutional |
28% |
|
Investor Calendar
|
|
1. What is the date of release of financial results?
|
|
The tentative calendar for the financial results for the fiscal year 2008 is as follows:
|
| Q1 FY 08 |
July 18, 2007 |
| Q2 FY08 |
October 18, 2007 |
| Q3 FY 08 |
January 18, 2008 |
| Q4 FY 08 |
April 19, 2008 |
|
2. When is the next AGM? |
The Annual General Meeting (AGM) of the Company for the year 2007-08 is proposed to be held on July 18, 2008
|
|
3. Does the Company have any quiet periods?
|
|
Yes. Biocon follows quiet periods prior to its quarterly results ie. starting at the end of the last quarter and ending on the day of announcement of earnings. During this time, the Company or any of its officials will not discuss earnings expectations with any external parties. Based on tentative dates of earnings release in fiscal 2008, the tentative quiet periods would be as follows:
|
| Quarter ending |
Earnings release date |
Quiet period |
| June 30, 2007 |
July 18, 2007 |
June 30, 2007 to Jul 18, 2007 |
| Sep 30, 2007 |
Oct 18, 2007 |
Sep 30, 2007 to Oct 18, 2007 |
| Dec 31, 2007 |
Jan 18, 2008 |
Dec 31, 2007 to Jan 18, 2008 |
| Mar 31, 2008 |
Apr 19, 2008e |
Mar 31, 2008 to Apr 19, 2008 |
|
Investor Contact Information
|
|
Investor Contact
|
|
- For queries relating to financial statement: |
|
Email: investor.relations@biocon.com
|
|
- For investor matters: |
|
Email: co.secretary@biocon.com
|
|
- For compliance matters and for matters relating to shares/dividend: |
|
Email: co.secretary@biocon.com
|
|
- Details of Registrar and Share Transfer Agents: |
|
Email: mahender@karvy.com
|
